Stock SPRY ARS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
11.11 USD +6.21% Intraday chart for ARS Pharmaceuticals, Inc. +22.22% +102.74%
Jul. 11 Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing MT
Jul. 11 Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing
MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing
MT
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Value Index
CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Value Index
CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000 Value Index
CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index
CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Microcap Value Index
CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index
CI
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion
MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen
RE
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
GL
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)
CI
Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing
MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
GL
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
GL
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp
CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand
CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. News ARS Pharmaceuticals, Inc.